• Best Practices New Normal
  • Digital Dentistry
  • Data Security
  • Implants
  • Catapult Education
  • COVID-19
  • Digital Imaging
  • Laser Dentistry
  • Restorative Dentistry
  • Cosmetic Dentistry
  • Periodontics
  • Oral Care
  • Evaluating Dental Materials
  • Cement and Adhesives
  • Equipment & Supplies
  • Ergonomics
  • Products
  • Dentures
  • Infection Control
  • Orthodontics
  • Technology
  • Techniques
  • Materials
  • Emerging Research
  • Pediatric Dentistry
  • Endodontics
  • Oral-Systemic Health

Vivos Therapeutics Files for Patent on New Clinical Sleep Apnea Protocols

Article

Vivos Therapeutics have announced filing for a patent for its sleep apnea treatment protocol the Vivos Method.

Vivos Therapeutics Files for Patent on New Clinical Sleep Apnea Protocols

Vivos Therapeutics Files for Patent on New Clinical Sleep Apnea Protocols

Sleep apnea technology company Vivos Therapeutics has announced that it is filing a U.S. patent application related to clinical protocols developed in the Vivos Method treatment for obstructive sleep apnea (OSA). The Vivos Method consists of both proprietary oral appliances as well as clinical methods and protocols, according to a press release from Vivos Therapeutics.

This application was created based on early field data that demonstrated a 58% average improvement in Apnea Hypopnea Index score reductions in OSA patients who had been treated using the Vivos Methods. As millions in the U.S. suffer from OSA, Vivos Chairman and CEO Kirk Huntsman says that it is all about enhancing the patient experience for them. 

“As an emerging market leader in technologies and protocols to treat patients with OSA, we continually seek to find new and innovative ways to further improve both patient experiences and clinical outcomes,” Huntsman said in the press release. “We believe these new methods and protocols are not only patentable but will enhance the positive experience that Vivos Method patients have reported.” 

The Vivos Method treatment is able to address dental tissue anomalies and malformations that are typically linked with OSA, and therapy is usually completed within 1 to 2 years.


Related Videos
Addressing Unmet Needs in Early Childhood Oral Care - an interview with Ashlet Lerman, DDS
2024 Chicago Dental Society Midwinter Meeting – Interview with Peter Maroon, business development and sales lead at Spectrum Solutions® on the new salivary diagnostic test, SimplyPERIO.
Product Bites – March 8, 2024 Part 2
Product Bites – March 8, 2024 Part 1
Contemporary Cosmetic Dentistry – Part II: Arresting Marginal Caries
GNYDM23 Product Focus: CandidPro with Kristin Lange, VP of Sales at Candid
Greater New York Dental Meeting 2023 – Interview with Suzanne Cano from LunaLite Dental
Greater New York Dental Meeting 2023 — Interview with Shannon Carroll, RDH
Greater New York Dental Meeting 2023 – Interview with Daniel Weinstein from Lura Health
© 2024 MJH Life Sciences

All rights reserved.